Hepatocellular carcinoma in older adults: Clinical features, treatments, and survival

Journal of the American Geriatrics Society

Volumn 59, Issue 2, 2011, Pages 241-250

  Lee, Sang Hyub ^a   Choi, Hyun Cheul ^a   Jeong, Sook Hyang ^a   Lee, Kwang Ho ^a   Chung, Jae Il ^a   Park, Young Soo ^a   Hwang, Jin Hyeok ^a   Kim, Jin Wook ^a   Kim, Nayoung ^a   Lee, Dong Ho ^a   Choi, Ho Cheol ^a   Yoon, Chang Jin ^a   Kang, Sung Gwon ^a  

^a Seoul National University Bundang Hospital   (South Korea)

Author keywords

elderly; hepatocellular carcinoma; prognosis; stage; treatment

Indexed keywords

ALPHA FETOPROTEIN; PEGINTERFERON; PEGINTERFERON ALPHA; RIBAVIRIN;

ADULT; AGED; AGING; ARTICLE; CANCER SURVIVAL; CANCER THERAPY; CHILD PUGH TURCOTTE SCORE; CLINICAL FEATURE; COMORBIDITY; DISEASE SEVERITY; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MODEL FOR END STAGE LIVER DISEASE SCORE; OVERALL SURVIVAL; PROGNOSIS; RETROSPECTIVE STUDY; SCORING SYSTEM; TUMOR VOLUME; UNIVERSITY HOSPITAL;

AGE FACTORS; AGED; CARCINOMA, HEPATOCELLULAR; CAUSE OF DEATH; DISEASE PROGRESSION; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 79951636227     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2010.03273.x     Document Type: Article

References (38)

1. Wan J, Grossman HB., Bladder carcinoma in patients age 40 years or younger. Cancer 1989; 64: 178-181. (Pubitemid 19167156)
2. Shaha AR, Shah JP, Loree TR., Risk group stratification and prognostic factors in papillary carcinoma of thyroid. Ann Surg Oncol 1996; 3: 534-538. (Pubitemid 126729002)
3. McGlynn KA, London WT., Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2005; 19: 3-23. (Pubitemid 40331495)
4. Dohmen K, Shigematsu H, Irie K, et al,. Comparison of the clinical characteristics among hepatocellular carcinoma of hepatitis B, hepatitis C and non-B non-C patients. Hepatogastroenterology 2003; 50: 2022-2027. (Pubitemid 37467986)
5. Yang BH, Xia JL, Huang LW, et al,. Changed clinical aspects of primary liver cancer in China during the past 30 years. Hepatobiliary Pancreat Dis Int 2004; 3: 194-198.
6. Jansen PL., Liver disease in the elderly. Best Pract Res Clin Gastroenterol 2002; 16: 149-158.
7. Pignata S, Gallo C, Daniele B, et al,. Characteristics at presentation and outcome of hepatocellular carcinoma (HCC) in the elderly. A study of the Cancer of the Liver Italian Program (CLIP). Crit Rev Oncol Hematol 2006; 59: 243-249. (Pubitemid 44294863)
8. Piccirillo JF, Tierney RM, Costas I, et al,. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004; 291: 2441-2447. (Pubitemid 38669187)
9. Oken MM, Creech RH, Tormey DC, et al,. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655. (Pubitemid 13149996)
10. Pugh RN, Murray-Lyon IM, Dawson JL, et al,. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-649.
11. Sheth M, Riggs M, Patel T., Utility of the Mayo End-Stage Liver Disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. BMC Gastroenterol 2002; 2: 2.
12. Trevisani F, Caraceni P, Bernardi M, et al,. Gross pathologic types of hepatocellular carcinoma in Italian patients. Relationship with demographic, environmental, and clinical factors. Cancer 1993; 72: 1557-1563. (Pubitemid 23249279)
13. Trevisani F, D'Intino PE, Caraceni P, et al,. Etiologic factors and clinical presentation of hepatocellular carcinoma. Differences between cirrhotic and noncirrhotic Italian patients. Cancer 1995; 75: 2220-2232.
14. Ramacciato G, Mercantini P, Cautero N, et al,. Prognostic evaluation of the new American Joint Committee on Cancer/International Union Against Cancer staging system for hepatocellular carcinoma: Analysis of 112 cirrhotic patients resected for hepatocellular carcinoma. Ann Surg Oncol 2005; 12: 289-297. (Pubitemid 40616493)
15. A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients: The Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998; 28: 751-755.
16. Kudo M, Chung H, Osaki Y., Prognostic staging system for hepatocellular carcinoma (CLIP score): Its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 2003; 38: 207-215. (Pubitemid 36527122)
17. Llovet JM, Bru C, Bruix J., Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis 1999; 19: 329-338.
18. Cantarini MC, Trevisani F, Morselli-Labate AM, et al,. Effect of the etiology of viral cirrhosis on the survival of patients with hepatocellular carcinoma. Am J Gastroenterol 2006; 101: 91-98. (Pubitemid 43381714)
19. Hofer H, Bankl HC, Wrba F, et al,. Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a. Am J Gastroenterol 2002; 97: 2880-2885. (Pubitemid 35265443)
20. Serfaty L, Andreani T, Giral P, et al,. Hepatitis C virus induced hypobetalipoproteinemia: A possible mechanism for steatosis in chronic hepatitis C. J Hepatol 2001; 34: 428-434. (Pubitemid 32240823)
21. Rodriguez C, Pablos-Mendez A, Palmas W, et al,. Comparison of modifiable determinants of lipids and lipoprotein levels among African-Americans, Hispanics, and Non-Hispanic Caucasians >or=65 years of age living in New York City. Am J Cardiol 2002; 89: 178-183. (Pubitemid 34132907)
22. Schupf N, Costa R, Luchsinger J, et al,. Relationship between plasma lipids and all-cause mortality in nondemented elderly. J Am Geriatr Soc 2005; 53: 219-226. (Pubitemid 41632547)
23. Dohmen K, Shirahama M, Shigematsu H, et al,. Optimal treatment strategy for elderly patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2004; 19: 859-865. (Pubitemid 39093201)
24. Tsukioka G, Kakizaki S, Sohara N, et al,. Hepatocellular carcinoma in extremely elderly patients: An analysis of clinical characteristics, prognosis and patient survival. World J Gastroenterol 2006; 12: 48-53. (Pubitemid 43126082)
25. Nakamuta M, Morizono S, Kohjima M, et al,. Baseline characterization of patients aged 70 years and above with hepatocellular carcinoma. World J Gastroenterol 2005; 11: 7512-7514. (Pubitemid 43126035)
26. Le Couteur DG, Warren A, Cogger VC, et al,. Old age and the hepatic sinusoid. Anat Rec (Hoboken) 2008; 291: 672-683.
27. Anantharaju A, Feller A, Chedid A., Aging liver. A review. Gerontology 2002; 48: 343-353.
28. Trevisani F, D'Intino PE, Grazi GL, et al,. Clinical and pathologic features of hepatocellular carcinoma in young and older Italian patients. Cancer 1996; 77: 2223-2232. (Pubitemid 26162413)
29. Zhou XD, Tang ZY, Yu YQ, et al,. Characteristics and prognosis of primary liver cancer in young patients in China. J Gastroenterol 1995; 30: 632-635.
30. Giannini E, Romagnoli P, Fasoli A, et al,. Influence of age on clinical presentation, therapeutic options, and prognosis in anti-HCV positive cirrhotic patients with hepatocellular carcinoma. Age Ageing 2002; 31: 457-462. (Pubitemid 35452791)
31. Falkson G, Cnaan A, Schutt AJ, et al,. Prognostic factors for survival in hepatocellular carcinoma. Cancer Res 1988; 48: 7314-7318. (Pubitemid 19014023)
32. Predictive factors for long term prognosis after partial hepatectomy for patients with hepatocellular carcinoma in Japan. The Liver Cancer Study Group of Japan. Cancer 1994; 74: 2772-2780.
33. Cho SJ, Yoon JH, Hwang SS, et al,. Do young hepatocellular carcinoma patients with relatively good liver function have poorer outcomes than elderly patients? J Gastroenterol Hepatol 2007; 22: 1226-1231.
34. Mirici-Cappa F, Gramenzi A, Santi V, et al,. Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: A 20-year multicentre experience. Gut 2010; 59: 387-396.
35. Ng IO, Ng MM, Lai EC, et al,. Pathologic features and patient survival in hepatocellular carcinoma in relation to age. J Surg Oncol 1996; 61: 134-137. (Pubitemid 26066074)
36. Burzynski SR., Aging: Gene silencing or gene activation? Med Hypotheses 2005; 64: 201-208. (Pubitemid 39469265)
37. Park BL, Kim YJ, Cheong HS, et al,. HDAC10 promoter polymorphism associated with development of HCC among chronic HBV patients. Biochem Biophys Res Commun 2007; 363: 776-781. (Pubitemid 47520686)
38. Li X, Hui AM, Sun L, et al,. p16INK4A hypermethylation is associated with hepatitis virus infection, age, and gender in hepatocellular carcinoma. Clin Cancer Res 2004; 10: 7484-7489. (Pubitemid 39557509)